How does KinAffinity® compare with commercially available in vitro kinase panels?
Hit profiling against a limited panel of recombinant kinases is routinely used to determine target activities in early drug discovery. Beyond the limitations of the kinase spectrum, these biochemical assays assess the activity in settings using isolated targets, regular recombinant protein enzymes or protein fragments, and in a non-physiological manner. In contrast to target based-screening, our chemical proteomics approach quantitatively determines compound-target profiles in an unbiased manner, using a ready-to-use matrix to capture and enrich a cell’s or tissue’s expressed kinome: In other words, interactions of a kinase inhibitor with endogenously expressed, full length and post-translationally modified target proteins in a physiological context, and in the presence of cellular co-factors and native partners. Furthermore, KinAffinity uses cells or tissue, and can therefore detect interactions with kinases not included in any commercially available kinase panel. So far, 341 non-redu
